Received May 5, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
No additional AE/No PQC reported.; HCP called to report a female patient, who is currently 15 years old, received her first dose of GARDASIL 9 on 01NOV2024 and will be receiving her second dose today on 01MAY2025. Caller was unable to provide patient name or age at time of first admi; This spontaneous report was received from a Pharmacist and refers to currently 15 years old female. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 01-Nov-2024, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (strength, dose, route, anatomical ocation, lot #, expiration date were not reported) for prophylaxis. It was mentioned that the patient would be receiving her second dose today on 01-MAY-2025. No symptoms reported. vide patient name or age at time of first admi. On an unknown date, the patient experienced No additional AE/No PQC reported.. At the reporting time, the outcome of HCP called to report a female patient, who is currently 15 years old, received her first dose of GARDASIL 9 on 01NOV2024 and will be receiving her second dose today on 01MAY2025. Caller was unable to provide patient name or age at time of first admi and No additional AE/No PQC reported. was unknown. The action taken with Human Papillomavirus 9-valent Vaccine, Recombinant was reported as not applicable.